J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jullien, V.
Right arrow Articles by Tréluyer, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jullien, V.
Right arrow Articles by Tréluyer, J.-M.

PEDIATRICS

Abacavir Pharmacokinetics in Human Immunodeficiency Virus–Infected Children Ranging in Age From 1 Month to 16 Years: A Population Analysis

Vincent Jullien, PharmD, Saïk Urien, MD, PhD, Hélène Chappuy, MD, Jérôme Dimet, PharmD, Elisabeth Rey, PharmD, Gérard Pons, MD, PhD, Stéphane Blanche, MD, PhD and Jean-Marc Tréluyer, MD, PhD

From Pharmacologie Clinique, Université René Descartes, Groupe Hospitalier Cochin-Saint-Vincent-de-Paul, Assistance Publique-Hôpitaux de Paris, Paris, France (Dr Jullien, Dr Urien, Dr Chappuy, Dr Dimet, Dr Rey, Dr Pons, Dr Tréluyer) and Hématologie Pédiatrique, Hôpital Necker-Enfants-Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Dr Blanche).

Abacavir pharmacokinetics was studied in 105 children by a population approach performed with NONMEM. A 1-compartment open model with linear absorption and elimination adequately described the data. Typical population estimates (percent interindividual variability) of absorption rate constant, apparent distribution volume, and apparent plasma clearance were 1.79 h–1 (58%), 42.9 L (53%), and 24.3 L/h (30%), respectively. Apparent plasma clearance was positively related to body weight. Individual Bayesian estimates of apparent plasma clearance were used to calculate individual abacavir area under the concentration curve (AUC). For the current weight-based regimen, abacavir exposure was found to be constant throughout the age range of the study, with an overall mean AUC value of 8.5 ± 2.5 mg·h/L, which is slightly greater than the mean AUC value reported in adults. This study confirms the relevance of the current weight-based abacavir dosage regimen in pediatric patients.

Key Words: Human immunodeficiency virus (HIV) • abacavir • children • body weight • population pharmacokinetics

Address for reprints: Vincent Jullien, Pharmacologie Clinique, Université René Descartes, Groupe Hospitalier Cochin-Saint-Vincent-de-Paul, Assistance Publique-Hôpitaux de Paris, 82 Avenue Denfert-Rochereau, 75674 Paris Cedex 14, France.




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
A. El-Tahtawy, H. Kokki, and B. E. Reidenberg
Population pharmacokinetics of oxycodone in children 6 months to 7 years old.
J. Clin. Pharmacol., April 1, 2006; 46(4): 433 - 442.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Clinical Pharmacology